NetworkNewsBreaks – Imagin Medical Inc.’s (CSE
Post# of 31
(Total Views: 154)
Posted On: 05/07/2021 4:02:48 PM
NetworkNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue(TM) Imaging System to Enable More Accurate Tumor Resection
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has made notable strides in its quest to offer innovative technology for visualizing cancer. Designed to address the limitations of both white and blue light cystoscopy procedures, IME’s i/Blue(TM) Imaging System displays real-time white and blue light images on the screen simultaneously. This eliminates the need for the surgeon to switch back and forth between images, as is the case with blue light cystoscopy. On the other hand, it addresses the limitation of the white light cystoscopy, which is notorious for not clearly defining the margins between flat tumor and non-affected bladder tissue. A recent article reads, “This advancement will eliminate the need to switch back and forth between images and enable more accurate tumor resection and possibly lower recurrence rates.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has made notable strides in its quest to offer innovative technology for visualizing cancer. Designed to address the limitations of both white and blue light cystoscopy procedures, IME’s i/Blue(TM) Imaging System displays real-time white and blue light images on the screen simultaneously. This eliminates the need for the surgeon to switch back and forth between images, as is the case with blue light cystoscopy. On the other hand, it addresses the limitation of the white light cystoscopy, which is notorious for not clearly defining the margins between flat tumor and non-affected bladder tissue. A recent article reads, “This advancement will eliminate the need to switch back and forth between images and enable more accurate tumor resection and possibly lower recurrence rates.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)